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AKTLung cancer is the leading cause of cancer related death, 90% of lung cancer patients die of metastasis. Many
microRNAs (miRNAs) are deregulated in cancer. They are involved in tumorigenesis and function as oncogenes
or tumor suppressor genes. Recent studies show that miRNAs may be responsible for tumor metastasis. Several
functional studies show that miR-26a plays an important role in carcinogenesis; however, none of these studies
is related to tumormetastasis. In the present study, we investigated the effect ofmiR-26a onmetastasis potential
of lung cancer cells. Our data showed that miR-26a expression level was higher in lymph nodemetastasis tumor
tissues than in primary tumor tissues. Ectopic expression of miR-26a dramatically enhanced lung cancer cell
migration and invasion abilities. Metastasis-related genes matrix metallopeptidase 2 (MMP-2), vascular endo-
thelial growth factor (VEGF), Twist and β-catenin were upregulated. Phosphatase and tensin homolog (PTEN)
was a direct target of miR-26a. Further mechanistic study revealed thatmiR-26a increased AKT phosphorylation
and nuclear factor kappa B (NFκB) transcriptional activation. Our study demonstrated that miR-26a enhanced
lung cancer cell metastasis potential via modulation of metastasis-related gene expression, and activation of
AKT pathway by PTEN suppression, suggesting that miR-26a might be a potential therapeutic candidate in
patients with metastatic lung cancer.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is themost common cause of death inmen and second
only to breast cancer in women. It accounts for 12.7% (1.6 million) of
the total cancer cases and 18.2% (1.4million) of the total cancer deaths
[1]. The most common form of lung cancer is non‐small-cell lung
cancer (NSCLC), which comprises approximately 80% of all lung
cancers. The overall 5-year survival rate associated with NSCLC is 15%.
About 40% of patients with NSCLC present at an advanced stage,
with metastatic or locally advanced disease, and nearly 90% of lung
cancer patients die of metastasis [2]. The metastatic cascade is a series
of biological processes that enable the movement of tumor cells from
the primary site to a distant location and the establishment of a new
cancer growth. It includes the following steps: invading the surround-
ing tissue, entering the microvasculature of the lymph and blood
systems (intravasation), surviving and translocating to microvessels of
distant tissues, exiting from the bloodstream (extravasation), surviving
in the microenvironment of distant tissues, and ﬁnally adapting to the
foreign microenvironment of these tissues in ways that facilitate cell
proliferation and the formation of a secondary tumor (colonization)+86 22 60363013.
l rights reserved.[3]. However, the mechanism of cancer cell metastasis is still poorly
understood.
MicroRNAs (miRNAs) are small non-coding RNAs of 20–22 nucleo-
tides. It represses gene expression through interaction with 3′
untranslated regions (3′-UTRs) of mRNAs. miRNAs are predicted to
target over 50% of all human protein-coding genes, enabling them to
have numerous regulatory roles in many physiological and develop-
mental processes, including development, differentiation, apoptosis
and proliferation, through imperfect pairing with target mRNAs of
protein-coding genes and the transcriptional or post-transcriptional
regulation of their expression. Many miRNAs are deregulated in
cancer. They are involved in tumorigenesis and function as oncogenes
or tumor suppressor genes [4,5]. Recent studies show that some
miRNAs control tumor cell invasion and metastasis. For instance,
miR-10b is highly expressed in metastatic breast cancer cells and
positively regulates cell migration and invasion [6]; miR-373 and
miR-520c promote breast cancer cell invasion and metastasis by sup-
pression of CD44 [7]; miR-126 inhibit NSCLC cell invasion by targeting
Crk [8]. The role of miR-26a in cancer cells seems controversial as it
served as an oncogene in glioma and T-cell acute lymphoblastic
leukemia but as a tumor suppressor in nasopharyngeal carcinoma,
breast cancer and liver cancer cells [9–14]. However, there is no
evidence of miR-26a in cancer metastasis been documented so far.
Table 1
PCR primer sequences.
Primers Sequence (5′–3′) Length of amplicons
(bp)
MMP-2 Forward
Reverse
GCGGCGGTCACAGCTACTT
CACGCTCTTCAGACTTTGGTTCT
71
VEGF Forward
Reverse
AGGAGGAGGGCAGAATCATCA
CTCGATTGGATGGCAGTAGCT
76
Twist Forward
Reverse
GCCAATCAGCCACTGAAAGG
TGTTCTTATAGTTCCTCTGATTGTTACCA
83
β-Catenin Forward
Reverse
GCTGGGACCTTGCATAACCTT
ATTTTCACCAGGGCAGGAATG
86
GAPDH Forward
Reverse
TGCACCACCAACTGCTTAGC
GGCATGGACTGTGGTCATGAG
87
MMP-2, matrix metallopeptidase 2; VEGF, vascular endothelial growth factor; GAPDH,
Glyceraldehyde-3-phoshate dehydrogenase.
1693B. Liu et al. / Biochimica et Biophysica Acta 1822 (2012) 1692–1704In this study, we investigated the potential role of miR-26a in lung
cancer cell metastasis. We assessed the expression level of miR-26a in
human lung cancer specimens and lung cancer cell lines, and examined
its effects on cell growth, migration, invasion and expression of
metastasis-related genes. Furthermore, we explored the target of
miR-26a in lung cancer cells, and the underliningmechanism of its func-
tion. This will provide better understanding of lung cancer metastasis.
2. Materials and methods
2.1. Materials
miR-26a mimics, inhibitor and control were purchased from
Genepharma (Shanghai, China). Antibodies against PTEN, NFκB p65,
AKT, p-AKT, MMP-2, Twist and PCNA were purchased from Cell Sig-
naling (Beverly, MA), antibodies against VEGF, β-catenin, histone H3
and α-tubulin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA), secondary antibodies coupled to HRP were pur-
chased from ZSGB-BIO (Beijing, China). Reverse transcription kit
and real-time PCR kit were purchased from TaKaRa Biotechnology
(Dalian, China). pNFκB-luc and pAP-1-luc were purchased from
Clontech (Mountain View, CA). Nuclear extraction kit was purchased
from Beyotime Institute of Biotech (Jiangsu, China).
2.2. Cell lines and clinical specimens
Human lung cancer cell lines A549, H661, SK-MES-1 and BEAS-2B
human normal lung bronchial epithelium cell line were purchased
from American Type Culture Collection (Manassas, VA). H661 cells
were grown and maintained in RPMI-1640 medium, A549 and
SK-MES-1 cells were grown and maintained in DMEM medium at
37 °C, 5% CO2. Medium was supplemented with 10% fetal bovine
serum, 100 U/mL penicillin and 100 U/mL streptomycin. BEAS-2B
cells were grown and maintained in Keratinocyte Supplementary
Free Medium with Supplement (GIBCO BRL, Grand Island, NY).
Lung cancer specimens were obtained from patients at the Tianjin
Cancer Hospital. Informed consent was obtained from each patient. The
study has been approved by the Hospital's Ethical Review Committee.
2.3. Cell proliferation assay
Cells were seeded at an initial density of 2×105cells/mL in a 6-well
plate and incubated with 0–200 nM of miR-26a mimics for 48 h at
37 °C. The cell viability was determined by Vi-CELL Cell Viability Analyzer
(BECKMANCOULTER, Brea, CA), following themanufacturer's instruction.
2.4. Wound healing assay
Cell migration was examined by wound healing assay as previously
described [15]. Brieﬂy, cells were cultured in six-well plates to 100%
conﬂuence. A plastic pipette tip was used to generate a clean wound
area across the center of the well. Cell debris was removed by washing
with PBS, and cells were allowed tomigrate in themedium. Thewound
was assessed by a microscope (Nikon, Tokyo, Japan) at ×40 magniﬁca-
tion at indicated time points. Cells in each ﬁeld of view were counted
by photographing through the microscope, and the average number
of cells present in each scrape with each treatment was determined.
At least ﬁve wound areas were investigated on each plate to quantify
the migration.
2.5. Cell invasion assay
The tumor cell invasion activity was assessed by Cell Invasion Kit
(CHEMICON INTERNATIONAL Inc., Billerica, MA) as previously
described [15]. It was performed in an Invasion Chamber, a 24-well
tissue culture plate with cell culture inserts. The inserts contain an8 μm pore size polycarbonate membrane, over which a thin layer of
ECMatrixTM is dried. Cells were suspended to a ﬁnal concentration
of 2×105cells/mL in serum free medium with 0.1% BSA. Cell suspen-
sions (300 μL) were added to the upper compartment, medium col-
lected from NIH3T3 cell culture was added with 0.1% BSA, then
added to the lower compartment, and incubated for 48 h at 37 °C in
5% CO2 atmosphere. Invasive cells on the lower surface of the mem-
brane were stained following the manufacturer's instruction, and
counted by photographing the membrane through the microscope
(×100 magniﬁcation).
2.6. Western blotting analysis
Western blottings were performed as previously described [16].
Brieﬂy, cells were incubated with miR-26a mimics for 48 h, washed
with PBS, and the cell pellets were prepared in lysis buffer (20 mM
Tris (pH7.5), 150 mMNaCl, 1% Triton X-100, sodium pyrophosphate,
β-glycerophosphate, EDTA, Na3VO4, leupeptin). Lysates were
electrophoresed on SDS-PAGE and transferred to nitrocellulose
membranes. Membranes were blocked for 1 h at room temperature
with 5% milk protein, 0.1% Tween 20 in PBS, then were probed with
rabbit anti‐PTEN, Akt, p-Akt antibodies at 1:1000 dilution in 0.1%
Tween 20 in PBS with 5% BSA overnight at 4 °C. After washing, the
membranes were probed with HRP-conjugated goat anti-rabbit anti-
body at 1:5000 dilution in 0.1% Tween 20 in PBS with 3%milk protein
for 1 h. The blots were developed with the Phototope HRP Western
Blot Detection system (Cell Signaling).
2.7. Real-time PCR
Total RNA was extracted from cells using Trizol (Invitrogen,
Carlsbad, CA). Reverse transcription was performed as preciously de-
scribed [17] using TaKaRa kit following manufacturer's instruction.
For gene expression, primers were synthesized by SBS Genetech
(Beijing, China). SYBR Green was used to quantify mRNA levels. All
real-time PCR reagents were purchased from TaKaRa Biotechnology
Co. PCR reactions were performed as preciously described [17] in
the ABI Prism 7500 Sequence Detector System (ABI, Foster City, CA).
The primers for MMP-2, VEGF, Twist, β-catenin and GAPDH were
listed in Table 1. The expression of miR-26a was detected using
Hairpin-it miRNAs qPCR Quantitation kit (GenePharma), following
manufacturer's instruction. U6 was used for normalization.
2.8. Construction of expression plasmid
The following primers were used to amplify and clone the 3′-UTR of
human PTEN into the pGL3 luciferase vector (Promega) according to
manufacturer's instruction. For predicted binding site one: forward
5′-GCTCTAGACAATCATAATACCTGCTGTGGA-3′, reverse 5′-CTAGCTAGC
TAAAGCACATGTAGGACAATTTC-3′. For predicted binding site two:
1694 B. Liu et al. / Biochimica et Biophysica Acta 1822 (2012) 1692–1704forward 5′-GCTCTAGACCATCCCCATAGAATTTGAC-3′, reverse 5′-CTAGC
TAGCTGATGCTGCCGGTAAACTC-3′. The forward primer includes an Xba
I restriction site, and the reverse primer has a Nhe I restriction site
(underlined) to facilitate ligation into the vector. Predicted miR-26a
binding sites were mutated using the TaKaRa MutanBEST Kit.
The following primers were used to amplify and clone the human
PTEN into the pCMV-tag2B vector (Agilent Technologies, Santa Clara
CA) according to manufacturer's instruction. Forward 5′-CGGGATCC
GACATGACAGCCATCATCAAAG-3′, reverse 5′-CCGCTCGAGTCAGACTT
TTGTAATTTGTGTATG-3′. The forward primer includes a Bam HI re-
striction site, and the reverse primer has an Xho I restriction site
(underlined) to facilitate ligation into the vector.
2.9. Transfection and luciferase assay
Cell transfection was carried out using lipofectamine 2000
(Invitrogen, Carlsbad, CA), following the manufacturer's instruction.
Brieﬂy, cells were plated in a 24-well plate at 1×105cells/well. Cells
were transfected with 100–200 nM of miR-26a mimics, or 100 ng of
pNFκB-luc, or 200 ng of 3′UTR of PTEN, and 1 ng of pRL-SV40 as an in-
ternal control. BothmiR-26amimics andmiR controlwere composed of
RNA duplexes with the following sequence, miR-26a mimics: sense
5′-UUCAAGUAAUCCAGGAUAGGCU-3′, anti-sense: 5′-CCUAUCCUGGAU
UACUUGAAUU-3′. Control: sense 5′-UUCUCCGAACGUGUCACGUTT-3′,
anti-sense 5′-ACGUGACACGUUCGGAGAATT-3′. The sequence ofFig. 1. Expression of miR-26a in human lung cancer cell lines and clinical specimens.
A) Relative expression of miR-26a in BEAS-2B cells and lung cancer cell lines A549,
SK-MES-1 and H661. B) Relative expression of miR-26a in human lung normal tissues,
primary tumor tissues and lymph node metastasis tumor tissues (n=10). Each set of
paired specimens was connected by lines. miRNA abundance was normalized to U6
RNA. Values represent the mean±SD from three independent measurements. Columns,
mean; bars, SD. ** Pb0.01, *** Pb0.001 versus control.miR-26a inhibitor was 5′-AGCCUAUCCUGGAUUACUUGAA-3′. The
sequence ofmiR-26a inhibitor control was 5′-CAGUACUUUUGUGUAGU
ACAA-3′. Luciferase assay was performed 24 h later using the
Dual-luciferase Reporter Assay System (Promega) following the
manufacturer's instruction, on BERTHOLD TriStar LB 941 (BERTHOLD
TECHNOLOGIES, Bad Wildbad, Germany). The sequences of siRNA du-
plex for PTEN: 5′-GGCGCUAUGUGUAUUAUUATT-3′, anti-sense: 5′-UAA
UAAUACACAUAGCGCCTT-3′.
2.10. Statistical analysis
The data were presented as mean±standard deviation (SD). Vari-
ance analysis between groups was performed by one-way ANOVA
and signiﬁcance of difference between control and treatment groups
was analyzed using Dunnett multiple comparison test. The differences
with pb0.05 were considered statistically signiﬁcant.
3. Results
3.1. MiR-26a was downregulated in human lung cancer cell lines and
clinical specimens
To deﬁne the role of miR-26a in human lung cancer tumorigenesis,
we compared the expression levels of miR-26a in three human lung
cancer cell lines, A549 (adenocarcinoma), SK-MES-1 (squamous cell
carcinoma), H661 (large cell carcinoma), with BEAS-2B (humanFig. 2. The effect ofmiR-26a on growth of human lung cancer cells. A) A549, SK-MES-1 and
H661 cells were transfected with 100–200 nM of miR-26a. The miR-26a expression levels
were detected by real-time-PCR. B) A549, SK-MES-1 and H661 cells were transfected
with 100–200 nM miR-26a. Cells were collected 48 h after and counted by a Vi-CELL Cell
Viability Analyzer. Values represent themean±SD from three independentmeasurements.
Fig. 3. MiR-26a enhanced the migration of lung cancer cells. A549, SK-MES-1 and H661 cells were transfected with 100 nM of miR-26a. Wound healing assays were performed to
assess cell migration after 24 and 48 h. A) Representative photographs of cells are presented (×40 magniﬁcation). B) Number of cells migrated at 24 and 48 h time point is
presented. C) H661 cells were transfected with 100 nM of miR-26a inhibitor. Wound healing assays were performed to assess cell migration after 24 and 48 h. Values represent
the mean±SD from three independent measurements. * Pb0.05,** Pb0.01, *** Pb0.001 versus control.
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Fig. 4.MiR-26a enhanced the invasion of lung cancer cells. A549, SK-MES-1 and H661 cells were transfected with 100 nM of miR-26a. Invasion Chamber assays were performed to
assess cell migration after 48 h. A) Representative photographs of cells are presented (×100 magniﬁcation). B) Number of cells invaded after 24 h is presented. C) H661 cells were
transfected with 100 nM of miR-26a inhibitor. Invasion Chamber assays were performed to assess cell migration after 48 h. Values represent the mean±SD from three independent
measurements. * Pb0.05 versus control.
1696 B. Liu et al. / Biochimica et Biophysica Acta 1822 (2012) 1692–1704normal lung bronchial epithelium) cell line. In H661 cells, the expres-
sion level of miR-26a was reduced to 74.1% compared with that of
BEAS-2B cells. In A549 and SK-MES-1 cells, the expression levels ofmiR-26a were further reduced to 38.5% and 38.4%, respectively
(Fig. 1A). These results indicated that miR-26a is signiﬁcantly
downregulated in human lung cancer cells.
Fig. 5. MiR-26a modulated metastasis-related gene expression. A549, SK-MES-1 and H661 cells were transfected with 100 nM of miR-26a or miR-26a inhibitor. A) mRNA expres-
sion of MMP-2, VEGF, Twist and β-catenin was detected 24 h after by real-time PCR. B) Protein expression level of MMP-2, VEGF, Twist and β-catenin in A549 cells was detected by
Western blotting analysis. Similar results were obtained in three independent experiments.
1697B. Liu et al. / Biochimica et Biophysica Acta 1822 (2012) 1692–1704We further detected the expression level of miR-26a in lung cancer
specimens. 10 sets of lung cancer specimens were collected, including
normal tissues, primary tumor tissues and lymph node metastasis
tumor tissues. Our data indicated that miR-26a is downregulated in
lung cancer specimens (*** Pb0.001). Interestingly, its expression
level was higher in lymph node metastasis tumor tissues than in
primary tumor tissues (** Pb0.01) (Fig. 1B).
3.2. MiR-26a had no effect on growth of human lung cancer cells
To investigate the function of miR-26a in the development of lung
cancer, we evaluated the effect of miR-26a on the growth of lung
cancer cells by transient transfection.We ﬁrst assessed the transfectionefﬁciency of miR-26a. A549, SK-MES-1 and H661 cells were transfected
with 100 or 200 nM of miR-26a, the miR-26a levels were detected by
stem-loop RT-PCR. The miR-26a levels were increased signiﬁcantly by
an average of 120-fold. Interestingly, the transfection of 200 nM of
miR-26a did not reach higher efﬁciency compared with transfection
of 100 nM of miR-26a (Fig. 2A).
Next we investigated the effect of miR-26a on lung cancer cell
growth. Cell proliferation was detected by Vi-CELL Cell Viability
Analyzer. Fig. 2B showed that both 100 and 200 nM of miR-26a had
no effect on cell proliferation, and 100 nM of miR-26a inhibitor had
no effect on cell proliferation. However, 200 nM of miR-26a inhibitor
slightly inhibited A549 cell growth. This may be due to the toxicity of
high concentration of miR-26a inhibitor in A549 cells.
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Fig. 6. PTEN is a direct target of miR-26a. A) Putative miR-26a binding sites in 3′-UTR of
PTEN. Nucleotide changes for binding site mutants are indicated. B) Relative activity of
the luciferase gene fused with the wild type (wt) or mutant (mt) 3′-UTR of PTEN. A549,
SK-MES-1 and H661 cells were transfected with 100 and 200 nM of miR-26a, or
100 nM of miR-26a inhibitor. The luciferase activities were measured after 24 h.
C) MiR-26a reduced the expression of PTEN. A549, SK-MES-1 and H661 cells were
transfected with 100 and 200 nM of miR-26a, or 100 nM of miR-26a inhibitor. The
expression levels of PTEN were detected by Western blot after 24 h. Similar results
were obtained in three independent experiments. D) Relative expression of PTEN in
human primary tumor tissues and lymph node metastasis tumor tissues (n=10).
Each set of paired specimens was connected by lines (** Pb0.01). E) Inverse correlation
between miR-26a and PTEN level in lung cancer specimens (Spearman's correlation
analysis, r=−0.792; ** Pb0.01).
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The effect of miR-26a on migration of lung cancer cells was exam-
ined by wound healing assay. A549, SK-MES-1 and H661 cells were
transfected with 100 nM of miR-26a, and cell migration was detected
after 24 and 48 h. As shown in Fig. 3A, B, the cell motility was enhanced
in a time-dependent manner. The migration levels were increased to
1.3-, 1.4- and 1.2-fold of control after 24 h for A549, SK-MES-1 and
H661 cells, respectively; increased to 1.9-, 3.0- and 1.4-fold of control
after 48 h, respectively. The migration of SK-MES-1 cells was affected
most dramatically. To conﬁrm the effect of miR-26a on cell migration,
miR-26a level was further knocked down by transfection with
100 nM of miR-26a inhibitor. Since H661 cells express the highest
basal level of miR-26a among these cancer cell lines, we did this test
in H661 cells. The migration levels were signiﬁcantly decreased
(Fig. 3C).
3.4. MiR-26a enhanced the invasion of lung cancer cells
Another important step for cancer cell metastasis is cell invasion.
The effect of miR-26a on cell invasion was assessed by transwell
assay. Cells were transfected with 100 nM of miR-26a and grown onreconstituted extracellular matrix (ECM). Invasive cells were stained
and counted under microscope after 24 h. A signiﬁcant increase in
the number of invasive cells was observed. The levels of invasion
were increased to 1.6-, 1.9- and 1.6-fold of control for A549,
SK-MES-1 and H661 cells, respectively (Fig. 4A, B). SK-MES-1 cells
were affected most dramatically. H661 cells were further transfected
with 100 nM of miR-26a inhibitor; the level of invasion was de-
creased (Fig. 4C). This was consistent with the wound healing assay.
3.5. MiR-26a modulated metastasis-related genes expression
As our results showed that miR-26a enhanced both cell migration
and invasion ability, this drove us to further investigate its effect on
metastasis-related genes. MMP-2, VEGF, Twist and β-catenin play
important roles in cancer metastasis, and they promote lung cancer
metastasis. By using real-time PCR technique, we detected mRNA
expression levels of these four genes 24 h after transfection with
100 nM of miR-26a. All these four metastasis-related genes were
up-regulated in A549, SK-MES-1 and H661 cells (Fig. 5A). In particular,
they were regulated most signiﬁcantly in A549 cells, in which MMP-2
level was increased by 7.7-fold of control, VEGF level was increased
by 2.3‐fold of control, Twist level was increased by 6.5‐fold of control,
and β-catenin level was increased by 3.5‐fold of control, respectively.
Meanwhile, they were modulated moderately in SK-MES-1 cells, in
which these four genes were upregulated by 1.2–1.4-fold. To conﬁrm
the effect of miR-26a on these genes, miR-26a was knocked down in
H661 cells by transfection with miR-26a inhibitor. Our data showed
that these four genes were downregulated by 0.45–0.67-fold. Fig 5B
showed that protein levels of these genes in A549 cells were increased
by miR-26a transfection; this was constant with mRNA results.
3.6. PTEN was a direct target of miR-26a
To elucidate the underlying mechanisms by which miR-26a exe-
cutes its function, we explored miR-26a targets using the TargetScan
bioinformatics algorithm. In particular, we focused on tumor suppres-
sor genes. We found that there were two potential binding sites in
the 3′-UTR of PTEN (Fig. 6A). This makes PTEN a particularly attractive
target for further study.
We performed luciferase reporter assay to determine whether
miR-26a could directly target the 3′-UTR of PTEN in lung cancer
cells. As 1247–1268 nt and 2604–2626 nt, oriented from 5′ end of
3′-UTR, were putative binding sites for miR-26a in 3′-UTR of PTEN,
we cloned these target sequences (wt) or the mutant sequence
(mt) into pGL3 luciferase vector immediately downstream of the ﬁre-
ﬂy luciferase gene. Nucleotide changes for binding site mutants were
indicated in Fig. 6A. A549, SK-MES-1 and H661 cells were then
transfected with wt or mt PTEN 3′-UTR vectors, and miR-26a mimic
or miR control. The results showed that the miR-26a mimic, at both
100 and 200 nM, signiﬁcantly decreased the luciferase activities of
wt 3′-UTR vector when compared with miR control. Whereas, lucifer-
ase activities of mt 3′-UTR vector were unaffected by transfection
with miR-26a (Fig. 6B). MiR-26a was then knocked down in H661
cells by transfection with miR-26a inhibitor. Our data showed that
miR-26a inhibitor increased the luciferase activities of wt 3′-UTR
vector (Fig. 6B).
We further investigated whether miR-26a expression regulated
the expression level of PTEN. A549, SK-MES-1 and H661 cells were
transiently transfected with miR-26a mimic or miR control, and
PTEN expression levels were detected by Western blot. As shown in
Fig. 6C, both 100 and 200 nM of miR-26a reduced the expression
level of PTEN in three cell lines. MiR-26a was then knockdown in
H661 cells by transfection with miR-26a inhibitor, and the expression
level of PTEN increased. Taken together, all these results strongly
indicated that PTEN was a direct target of miR-26a.
Fig. 7. PTENmediated the effect of miR-26a on migration and invasion of lung cancer cells. A) H661 cells were transfected with 2 μg of pPTEN vector or 100 nM of siRNA duplex. The
expression levels of PTEN were detected by Western blot. B) Wound healing assays were performed to assess cell migration after 48 h. C) Invasion Chamber assays were performed
to assess cell migration after 48 h.
1700 B. Liu et al. / Biochimica et Biophysica Acta 1822 (2012) 1692–1704Next we detected the expression level of PTEN in lung cancer
specimens. We found that PTEN expression level was lower in
lymph node metastasis tumor tissues than in primary tumor tissues
(** Pb0.01) (Fig. 6D), and inversely correlated with miR-26a level
(r=−0.792; ** Pb0.01) (Fig. 6E).
3.7. PTEN mediated the effect of miR-26a on migration and invasion of
lung cancer cells
To investigate the effect of PTEN on migration and invasion of lung
cancer cells, PTEN was overexpressed by pPTEN vector or knockdown
byRNA interfering inH661 cells (Fig. 7A).Wound healing assay showed
that PTEN knockdown enhanced cell motility, and PTEN overexpression
abolished the enhancement of cell migration by miR-26a (Fig. 7B).
Similarly, transwell assay also demonstrated that PTEN knockdown
enhanced cell invasion, and the enhancement of cell invasion by
miR-26a was attenuated by PTEN overexpression (Fig. 7C).
3.8. AKT pathway contributed to the enhanced metastasis potential
induced by miR-26a
There are several signaling pathways involved in cancer cell me-
tastasis, one of them is the AKT pathway. PTEN functions as a tumorsuppressor, and it negatively regulates AKT signaling pathway. This
promoted us to investigate the effect of miR-26a on AKT pathway.
AKT activation was detected by Western blot. As shown in Fig. 8A,
after transfection with 100 and 200 nM of miR-26a, the phosphoryla-
tion levels of AKT in A549, SK-MES-1 and H661 cells were increased
dramatically, whereas the total AKT levels remained unchanged.
When H661 cells were transfected with 100 nM of miR-26a inhibitor,
the phosphorylation levels of AKT decreased. We next examined the
downstream molecule of AKT, the nuclear factor NFκB. The transcrip-
tional activation of NFκB was assessed by luciferase reporter assay.
After transfection with miR-26a, the luciferase activities were
increased in all three cell lines (Fig. 8B). NFκB activation was also
assessed by nuclear translocation assay in H661 cells. Western blot
results showed that after transfection with miR-26a, the nuclear
NFκB level increased, whereas cytoplasmic NFκB level decreased.
When cells were transfected with miR-26a inhibitor, the nuclear
NFκB level decreased, whereas cytoplasmic NFκB level increased
(Fig. 8C).
The transcription factor activator protein 1 (AP-1) is one of the
genes regulated by NFκB; it controls a number of cellular processes in-
cluding cell proliferation, differentiation, apoptosis and metastasis. We
examined the AP-1 transcriptional activation by luciferase reporter
assay. Our data showed that miR-26a increased AP-1 transcriptional
Fig.7 (continued).
1701B. Liu et al. / Biochimica et Biophysica Acta 1822 (2012) 1692–1704activation in A549, SK-MES-1 and H661 cells (Fig. 8D). The effect of
miR-26a was also examined by miR-26a inhibitor in H661 cells by
luciferase reporter assay. MiR-26a inhibitor decreased transcriptional
activation of NFκB and AP-1 (Fig. 8E). Taken together, these results
demonstrated that miR-26a stimulated AKT pathways.4. Discussion
Metastasis is the most signiﬁcant process affecting the clinical
management of cancer patients. However, the molecular pathways
underlying each step still remain unclear. Although the oncogenic or
tumor-suppressing functions of miRNAs have been characterized,
the mechanistic roles played by miRNAs speciﬁcally in mediating
metastasis have been addressed only recently [18,19].
There is a study showing that miR-26a was downregulated in lung
cancer tissues, but no reports are available about its functions in lung
cancer [20]. Our results showed that the expression levels of miR-26a
were lower in tumor tissues than in adjacent normal lung tissues,
and lower in lung cancer cell lines than in normal lung bronchial
epithelium. Interestingly, we found that the expression levels of
miR-26a in lymph nodemetastasis tissues were higher than in primary
tumor tissues. Jiang et al. reported that expression level of
miR-125a-5p was lower in NSCLC tissues than in adjacent normal
lung tissues, but it enhanced cell migration and invasion [21]. This
drove us to investigate the role of miR-26a in tumor cell metastasis.
We selected A549, SK-MES-1, H661 cells, which exhibit similar clinical
phenotypes of lung adenocarcinoma, squamous cell carcinoma and
large cell carcinoma, respectively, as models for further study.
We ﬁrst examined the effect of miR-26a on cell growth. Our
results showed that miR-26a had no effect on lung cancer cell growth.
Numerous studies showed that miR-26a suppressed cell proliferation
in nasopharyngeal carcinoma, breast cancer and liver cancer cells
[11–13], but promoted cell proliferation in glioma [9,10]. Interesting-
ly, in leukemia, miR-26a inhibited acute myeloid leukemia cell
growth, whereas stimulated T-cell acute lymphoblastic leukemia
cell proliferation [14,22]. These controversial results suggested that
miR-26a might play different roles depending on tumor and tissue
types.Metastasis is the most common cause of death in cancer patients.
To elucidate the effect of miR-26a on lung cancer cell metastasis
potential, we performed wound healing and transwell chamber assays.
Our results demonstrated that miR-26a enhanced lung cancer cell mi-
gration and invasion in vitro. We then detected the effect of miR-26a
on expression of metastasis-related genes. Matrix metalloproteinases
(MMPs) are essential proteases involved in adhesion, invasion and
migration of cancer cells. MMP-2 belongs to MMPs family. It highly
expresses in tumor tissue, activates several key molecules leading to
rapid cellular proliferation, increased motility, invasion and angiogene-
sis. Downregulation of MMP-2 inhibited tumor cell invasion [23,24].
Angiogenesis is the process of new blood vessel formation, and it is
critical for the growth and metastasis of tumors. VEGF is a pro-
angiogenic growth factor, and plays important role in tumor
metastasis. Recently, antiangiogenesis agents that target the VEGF/
VEGF receptor pathway have become an important part of standard
therapy in multiple cancer indications [25,26]. Twist is a master regula-
tor of epithelial–mesenchymal transition (EMT) and metastasis, and it
contributes to metastasis by promoting EMT. Twist over-expression
correlates with tumor metastasis, and depletion of Twist efﬁciently
suppresses cell migration and invasion [27,28]. Cancer metastasis is
often associated with activation of the Wnt/β-catenin signaling path-
way. Upregulation of β-catenin promotes metastasis whereas
downregulation of β-catenin inhibits metastasis [29,30]. We found
that miR-26a upregulated MMP-2, VEGF, Twist and β-catenin. These
data demonstrated that miR-26a promoted lung cancer cell metastasis
by modulating metastasis-related genes.
To further explore the underlying mechanism, we investigated the
targets of miR-26a. There have been several miR-26a targets
reported, such as EZH2 [11], MTDH [13], GSK3β [31], interleukin-6
[32], interleukin-2 [33], SMAD1 [34], CCND2 [12], CCNE2 [12], RB1
[10] and MAP3K2 [10]. Also, two studies showed that PTEN is an
miR-26a target in glioma [9,10]. However, none of these studies was
related to tumor metastasis. In this study, we found a novel function
of miR-26a on cancer metastasis. MiR-26a enhanced lung cancer cell
metastasis potential by directly targeting PTEN. PTEN is a tumor sup-
pressor, and it negatively regulates AKT/PKB signaling pathway. PTEN
is one of the most mutated and deleted tumor suppressors in human
cancer, and it is also found partially downregulated in cancer in the
Fig. 8.MiR-26a stimulated AKT signaling pathway. A) A549, SK-MES-1 and H661 cells were transfected with 100 nM and 200 nM of miR-26a, or 100 nM of miR-26a inhibitor. AKT
and pAKT levels were detected by Western blot. B) Cells were transfected with 100 nM of miR-26a and pNFκB-luc. NFκB transcriptional activation was detected by luciferase re-
porter assay. C) H661 cells were transfected with 100 nM of miR-26a or miR-26a inhibitor, and NFκB nuclear translocation was detected by Western blot. D) Cells were transfected
with 100 nM of miR-26a and pAP-1-luc. AP-1 transcriptional activation was detected by luciferase reporter assay. E) H661 cells were transfected with 100 nM of miR-26a inhibitor
and pNFκB-luc or pAP-1-luc. NFκB and AP-1 transcriptional activation was detected by luciferase reporter assay. Values represent the mean±SD from three independent
experiments.
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1703B. Liu et al. / Biochimica et Biophysica Acta 1822 (2012) 1692–1704absence of genetic loss or mutation [35,36]. PTEN plays an important
role in tumor metastasis. Loss of PTEN is associated with gallbladder
adenocarcinoma metastasis [37], melanoma metastasis [38] and
mammary metastasis [39,40]. Our results showed that miR-26a re-
pressed PTEN expression, increased AKT phosphorylation and NFκB
transcriptional activation. Our ﬁndings demonstrated that miR-26a
enhanced lung cancer cell metastasis potential via activation of the
AKT/NFκB pathway by PTEN suppression.5. Conclusion
This study elucidates a novel function of miR-26a. miR-26a en-
hanced lung cancer cell metastasis potential by modulating
metastasis-related genes, and targeting PTEN/AKT/NFκB pathway.
Further in vivo study is needed for a deeper analysis of its functional
roles, before miR-26a becomes a potential target for treatment of
lung cancer and even other cancers.Acknowledgements
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